Totten S, MacLean R, Payne E, Severini A
Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON.
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB.
Can Commun Dis Rep. 2015 Feb 5;41(2):20-25. doi: 10.14745/ccdr.v41i02a01.
Chlamydia continues to be the most commonly reported sexually transmitted infection in Canada. Lymphogranuloma venereum (LGV), caused by certain serovars of , is becoming established in some populations in a number of Western countries.
To identify trends in reported cases of chlamydia and LGV in Canada from January 1, 2003 to December 31, 2012.
Notifiable disease data on chlamydia were submitted to the Public Health Agency of Canada by provincial and territorial epidemiological units and summarized at the national level by age and sex. Confirmatory testing for suspected LGV cases and serovar subtyping were performed by the National Microbiology Laboratory (NML). Where possible, provincial/territorial health authorities use a standardized national case report form to collect enhanced epidemiological data on each case and to submit the data to the Agency.
Rates of reported cases of chlamydia increased by 57.6%, from 189.6 to 298.7 per 100,000 between 2003 and 2012. The rate of reported cases of chlamydia among females (383.5 per 100,000) was almost twice as high as that among males (212.0 per 100,000), although the highest relative rate increase occurred among males. In both males and females, the rates of chlamydia were highest in those aged 20 to 24 years. From 2004 to 2012, 170 cases of LGV were reported to the Agency by provincial health authorities (including 104 confirmed and 66 probable cases). In 2012, case reports were received on 12 confirmed and probable cases, compared to 38 laboratory-positive cases confirmed by the NML.
In Canada, as in many countries, chlamydia rates have markedly increased over the last 10 years, in part due to improved diagnosis through nucleic acid amplification (NAAT) testing. Consistent with trends in Europe and other countries, LGV is emerging in Canada among men who have sex with men (MSM).
衣原体感染仍是加拿大报告最多的性传播感染。由沙眼衣原体某些血清型引起的性病性淋巴肉芽肿(LGV),正在一些西方国家的部分人群中出现。
确定2003年1月1日至2012年12月31日期间加拿大衣原体和LGV报告病例的趋势。
省级和地区级流行病学单位向加拿大公共卫生局提交衣原体的法定报告疾病数据,并在国家层面按年龄和性别进行汇总。国家微生物实验室(NML)对疑似LGV病例进行确证检测和血清型分型。省级/地区卫生当局尽可能使用标准化的国家病例报告表收集每个病例的强化流行病学数据,并将数据提交给该机构。
2003年至2012年期间,衣原体报告病例率上升了57.6%,从每10万人189.6例增至298.7例。女性衣原体报告病例率(每10万人383.5例)几乎是男性(每10万人212.0例)的两倍,尽管男性的相对增长率最高。在男性和女性中,衣原体发病率在20至24岁年龄组中最高。2004年至2012年,省级卫生当局向该机构报告了170例LGV病例(包括104例确诊病例和66例疑似病例)。2012年,收到了12例确诊和疑似病例的报告,而NML确认的实验室阳性病例为38例。
在加拿大,与许多国家一样,衣原体发病率在过去10年中显著上升,部分原因是通过核酸扩增(NAAT)检测改善了诊断。与欧洲和其他国家的趋势一致,LGV在加拿大男男性行为者(MSM)中出现。